the FDA determined that Revive’s proposed amended endpoint protocol, while still under review, does not support the time to resolution via the polymerase chain reaction (PCR) test.
When I first read this in the pr my understanding was that the trial data presented to the fda was not significant enough to justify revives, time to resolution, endpoint change request.
After reading dales report it seems thats not the case but rather that the submission by revives team was flawed because they relied on the now diminished method of pcr testing as core to their request.
Is this your impression also or did i misunderstand the article???